ProCE Banner Series

HER2-, HER3-, and TROP2-Targeted ADCs: Latest Progress, Future Possibilities, and Advancing the Therapeutic Relational Connection

Join expert advanced practice provider faculty to learn the latest about HER2-, HER3-, and TROP2-targeted antibody–drug conjugates in the care of patients with solid tumors, including case discussions, clinical considerations/adverse event management, patient counseling recommendations, and audience questions and answers.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients treated with HER2-, HER3-, and TROP2-targeted ADCs.

All Events

HER2-, HER3-, and TROP2-Targeted ADCs: Latest Progress, Future Possibilities, and Advancing the Therapeutic Relational Connection

Upcoming Events

November

13

2024

6:30 PM - 8:30 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Sara Cooper, MSN, RN, ACNP-BC, AOCNP-BC

Breast Oncology Nurse Practitioner
MemorialCare Cancer Institute
MemorialCare Medical Group
Orange County, California

ProCE Banner Faculty
Kristi K. Orbaugh, MSN, RNP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana

ProCE Banner Faculty
Kimberly Podsada, MSN, NP-C

Oncology Nurse Practitioner
UCSD Comprehensive Breast Health Center
La Jolla, California

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge and competence to optimize outcomes in patients treated with HER2-, HER3-, and TROP2-targeted ADCs.

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients treated with HER2-, HER3-, and TROP2-targeted ADCs.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss how structural, mechanistic, and unique characteristics, including the “bystander effect,” of antibody-drug conjugates contribute to differing toxicities and adverse event profiles
  • Proactively monitor for and manage AEs of ADC therapy using recommended approaches and a multidisciplinary care team
  • Use enhanced communication strategies, tools, and resources to counsel patients on AEs of ADCs
  • Advance the therapeutic relational connection with patients to identify and address barriers to optimal outcomes, including socioeconomic and geographic barriers and healthcare disparities

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by educational grants from AstraZeneca and Gilead Sciences, Inc.